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eter J. Mason, MD, MPH, Alice K. Jacobs, MD, FACC, Jane E. Freedman, MD, FACC
oston, Massachusetts
Acute coronary syndromes and other manifestations of atherothrombotic disease are primarily
caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or subocclusive
thrombus formation. Platelets play a critical role in the pathophysiology of atherothrombotic
disease, and aspirin is the most commonly used antiplatelet agent. Clinical trials have
demonstrated the efficacy of aspirin in both primary and secondary prevention of myocardial
infarction, stroke, and cardiovascular death. Despite its proven benefit, the absolute risk of
recurrent vascular events among patients taking aspirin remains relatively high, an estimated
8% to 18% after two years. Therapeutic resistance to aspirin might explain a portion of this
risk. Although formal diagnostic criteria and a validated method of measurement are lacking,
aspirin resistance may affect between 5% and 45% of the population. Given the prevalence of
cardiovascular disease, the potential impact of aspirin resistance is large. Currently, however,
there are many unanswered questions regarding the biological mechanism, diagnosis,
population prevalence, clinical relevance, and optimal therapeutic intervention for aspirin
resistance. (J Am Coll Cardiol 2005;46:986–93) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.070Cardiology Foundation
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che spectrum of acute coronary syndromes including un-
table angina, non–ST-segment elevation myocardial in-
arction (MI), ST-segment elevation MI, and sudden death
ccount for more than two million hospitalizations and 30%
f all deaths in the U.S. each year. The majority of acute
oronary syndromes are caused by atherosclerotic plaque
upture or fissuring and subsequent occlusive or subocclusive
hrombus formation. Plaque rupture exposes the contents of
he lipid core and promotes platelet adhesion and activation
f the extrinsic coagulation cascade. Activated platelets then
elease a variety of vasoactive substances, including throm-
oxane (TX)A2 and adenosine diphosphate (ADP), that
romote platelet aggregation and primary hemostasis. Sec-
ndary hemostasis occurs as a result of thrombin-mediated
onversion of fibrinogen to fibrin and subsequent stabiliza-
ion of the platelet aggregate.
In atherothrombosis, the most commonly used inhibitor
f platelet function is aspirin. The potential antithrombotic
ffects of aspirin were first reported in the Mississippi Valley
edical Journal in 1953 (1). Since that time, numerous
nvestigations have contributed to our understanding of
spirin’s antiplatelet effects and its potential role in the
reatment of atherothrombotic disease. Clinical trials have
ubsequently demonstrated that aspirin is effective for both
rimary and secondary prevention of MI, stroke, and
ardiovascular death (2,3) and in the acute management of
I, unstable angina, and embolic stroke (4–6). A recent
eta-analysis reported that, among high-risk vascular pa-
ients, aspirin therapy was associated with a 34% reduction
n nonfatal MI, a 25% reduction in nonfatal stroke, and an
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ccepted August 23, 2004.8% reduction in all-cause mortality (4). Atherothrombosis,
owever, is a complex physiological process, and the abso-
ute risk of recurrent vascular events among patients taking
spirin remains relatively high, an estimated 8% to 18% after
wo years. This suggests that the antiplatelet effects of
spirin may not be equivalent in all patients and/or that
ultiple therapeutic agents may be necessary to effectively
lock platelet function (Fig. 1).
Measurements of platelet aggregation, platelet activation,
nd bleeding time have all confirmed variability in patients’
ntithrombotic responses to aspirin therapy (7–10). Pro-
pective clinical studies have demonstrated that decreased
esponsiveness to aspirin therapy is associated with an
ncreased risk of atherothrombotic events (7,11–13). Recent
ardiovascular trials demonstrating the benefits of alternate
ntiplatelet agents such as the thienopyridine derivatives,
sed independently or in combination with aspirin, high-
ight the clinical importance of achieving appropriate levels
f platelet inhibition in preventing atherothrombosis (5,14–
6). These observations and others have contributed to the
oncept of aspirin resistance. Although formal diagnostic
riteria are lacking, aspirin resistance generally describes the
ailure of aspirin to produce an expected biological response
i.e., platelet inhibition) or the failure of aspirin to prevent
therothrombotic events.
Given the prevalence of cardiovascular disease, the po-
ential impact of aspirin resistance is large. Although the
revalence of aspirin resistance remains uncertain, previous
tudies have reported that it may affect between 5% and 45%
f the population (Table 1). Therefore, identifying aspirin
onresponders and achieving appropriate levels of platelet
nhibition with alternate therapy might have significant
linical impact. It has been hypothesized, for example, that
ual antiplatelet therapy may have particular utility among
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September 20, 2005:986–93 Aspirin Resistance and Atherothrombotic Diseasespirin-resistant patients (17). Currently, there are many
nanswered questions regarding the biological mechanism,
iagnosis, clinical relevance, and treatment of aspirin
esistance.
SPIRIN
echanism of action. The antiplatelet effects of aspirin are
ell-described and have been reviewed elsewhere (18,19).
spirin achieves its primary antithrombotic effect by interfer-
ng with platelet aggregation, and it does this by inactivation of
yclooxygenase (COX), a key enzyme in platelet arachidonate
etabolism. More specifically, aspirin inhibits the COX activ-
igure 1. Platelet function and mechanisms of antiplatelet therapy. ADP
Abbreviations and Acronyms
ADP  adenosine diphosphate
CAD  coronary artery disease
COX  cyclooxygenase
CRP  C-reactive protein
MI  myocardial infarction
NSAIDs  non-steroidal anti-inflammatory drugs
PFA  platelet function analyzer
PG  prostaglandin
PGH2  prostaglandin H2
PGI2  endothelium-derived prostacyclin
PURSUIT  Platelet IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrilin
Therapy trial
RPFA  rapid platelet function assay
TX  thromboxaneP  glycoprotein; PG  prostaglandin; P2  type 2 platelet purinergic recept
hydroperoxyeicosatetraenoic acid.ty of prostaglandin (PG)H-synthase, which in turn blocks the
etabolism of arachidonic acid to prostaglandin H2 (PGH2),
he precursor of TXA2 and other cyclic prostanoids (prostacy-
lin and other PGs). In human platelets, TXA2 is synthesized
nd released in response to a variety of stimuli (i.e., collagen,
DP, thrombin, platelet activating factor) and acts to amplify
he activation signal, promote irreversible platelet aggregation,
nd cause vasoconstriction (Fig. 1). Cyclooxygenase activity is
nhibited by aspirin via the acetylation of a single serine residue
t position 529 (Ser529) within platelet PGH-synthase. There
re two COX isoforms, but only the first (COX-1) is consti-
utively expressed in mature platelets. Because platelets have
inimal capacity for protein synthesis, the inactivation of
OX-1 by aspirin is irreversible for the life of the platelet (8 to
0 days). The second COX isoform (COX-2) is inducible in
ewly formed platelets (8% to 10% of circulating platelets), and
rostaglandin E2 is the main product of platelet COX-2
ctivity (20). The concentration of newly formed platelets is
arge enough during periods of increased platelet turnover to
roduce detectable amounts of COX-2–derived TXA2 (21);
owever, the clinical relevance of these observations is un-
nown. Cyclooxygenase-2 has been detected in a variety of cell
ypes, tissue distributions, and its role in inflammatory disor-
ers is widely recognized. The relatively weak anti-
nflammatory effect of aspirin at low doses (81 to 325 mg/day)
s in part explained by the fact that aspirin has 170-fold more
otent inhibition of COX-1 than COX-2 (18).
Platelet adhesion and aggregation are inhibited by a
enosine diphosphate; Ecs  endothelial cells; Gi  inhibitory G protein; ad
or; TX  thromboxane; HETE  hydroxyeicosatetraenoic acid; HPETE
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Aspirin Resistance and Atherothrombotic Disease September 20, 2005:986–93umber of endogenous mechanisms including endothelium-
erived prostacyclin (PGI2), nitric oxide, and platelet cell
olecule-1. Aspirin inhibits endothelium-derived PGI2
roduction in a dose-dependent manner and may thereby
ntagonize its antiplatelet effects. Unlike platelets, however,
ndothelial cells rapidly recover COX activity and make this
spirin-mediated effect short-lived, dose-dependent, and
erhaps less important when compared to the antiplatelet
ffect (17).
Aspirin may also influence hemostasis and cardiovascular
isease by mechanisms independent of PG production.
lthough less clearly defined, the non–PG-mediated effects
f aspirin on hemostasis are thought to be dose-dependent
nd unrelated to COX-1 activity. These effects include
itamin K antagonism, decreased platelet production of
hrombin, and acetylation of one or more clotting factors
18). Aspirin might also impair platelet function by inhib-
ting neutrophil-mediated platelet activation (19). In addi-
ion to its direct platelet effects, aspirin could potentially
lter the pathogenesis of cardiovascular disease by protecting
ow-density lipoprotein from oxidative modification, im-
roving endothelial dysfunction in atherosclerotic patients,
nd by attenuating the inflammatory response by acting as
n antioxidant (19).
able 1. Prevalence of Aspirin Resistance
Population Study Size Aspirin (mg/
ealthy subjects
Marshall et al. (38) n  12 750 three time
Pappas et al. (9) n  31 325
erebrovascular disease
Grotemeyer et al. (7) n  180 500
Helgason et al. (40) n  306 325
Grundmann et al. (41) Symptomatic, n  35 100
Asymptomatic, n  18
eripheral vascular disease
Mueller et al. (45) n  100 325
AD
Buchanan et al. (8) CABG, n  40 325
Macchi et al. (39) Stable CAD, n  72 160
Andersen et al. (43) Stable CAD, n  129 1. Aspirin alon
(160)
2. Aspirin (75)
warfarin
Wang et al. (35) Stable CAD, n  422 325
Gum et al. (12) Stable CAD, n  325 325
Chen et al. (13) Elective PCI, n  151 80–325
DP adenosine diphosphate; ARU aspirin resistance units; ASA aspirin; CAB
oronary intervention; RPFA  rapid platelet function assay.The anti-inflammatory properties of aspirin are intrigu- ong but not well-understood. A nested case-control study
ithin the Physician Health study demonstrated that the
ardioprotective effects of aspirin were primarily observed
mong men whose C-reactive protein (CRP) levels were
ithin the highest quartile and that men with CRP levels in
he lowest quartile had a lesser, nonsignificant benefit (22).
ubsequent prospective studies have failed to demonstrate a
onsistent relationship between low- and moderate-dose
spirin therapy and reduction in CRP levels (23–25).
owever, pretreatment with aspirin has been shown to
nhibit inflammation-mediated endothelial dysfunction, al-
hough the mechanism for this effect is unknown (26).
dditionally, in healthy subjects, low-dose aspirin therapy
as been shown to reduce platelet release of interleukin-7
nd to reduce plasma levels of this cytokine (27). These
ndings suggest that part of aspirin’s benefit might be
ediated through a reduction in vascular inflammation.
harmacology. The pharmacokinetic properties of aspirin
re marked by rapid absorption from the gastrointestinal
ract and peak plasma concentrations within 30 to 40 min of
ngestion. A significant platelet inhibitory effect is noted
ithin 60 min of ingestion, and a single dose of 100 mg of
spirin can completely block TXA2 production for the life of
he platelet in most individuals (28,29). The plasma half-life
Measurement of Platelet Function Aspirin Resistance
PFA-100 8.3%
Whole blood aggregometry using
ADP, arachidonic acid,
epinephrine, and collagen
N/A
Platelet reactivity: aggregation
induced by blood collection
36%
Optical platelet aggregometry using
ADP, arachidonic acid,
epinephrine, and collagen
25%
PFA-100 Symptomatic, 34%
Asymptomatic, 0%
Whole blood aggregation response
to ADP and collagen agonists
60%
Bleeding time 43%
PFA-100: defined ASA resistance as
epinephrine closure time 186 s
29.2%
PFA-100: defined ASA resistance as
epinephrine closure time 196 s
Aspirin alone, 35%
Aspirin plus warfarin, 40%
RPFA: defined ASA resistance
ARU 550
23%
1. Optical platelet aggregation: ADP
and arachidonic acid
1. 5.5%
2. PFA-100 (collagen/ADP and
collagen/epinephrine)
2. 9.5%
RPFA: defined ASA resistance
ARU 550
19.2%
coronary artery bypass grafting; CAD coronary artery disease; PCI percutaneousday)
s/day
e
plusf aspirin is approximately 20 min, but the irreversible
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September 20, 2005:986–93 Aspirin Resistance and Atherothrombotic Diseaseature of aspirin’s inhibition of platelet COX-1 activity and
uration of TXA2 suppression means that the antithrom-
otic effects of aspirin are maintained with dosing intervals
f 24 to 48 h (30).
Randomized trials have demonstrated that aspirin’s ther-
peutic benefits are achieved from a variety of doses (30 to
,500 mg/day), but the optimal daily dose has not been
nequivocally determined (3,4). In general, higher dose
egimens (500 to 1,500 mg/day) are not associated with
ignificant added benefit, might actually attenuate the anti-
hrombotic effect of aspirin, and have been associated with
ncreased risk of adverse effects (18). A recently published
etrospective analysis of patients with acute coronary syn-
romes enrolled in the Global Utilization of Streptokinase
nd Tissue Plasminogen Activator for Occluded Coronary
rteries (GUSTO) IIb and Platelet IIb/IIIa in Unstable
ngina: Receptor Suppression Using Integrilin Therapy
PURSUIT) trials failed to demonstrate a significant differ-
nce in six-month outcomes among patients taking low-
ose (150 mg/day) and intermediate-dose (150 mg/day)
spirin (31).
easurement of platelet function. Assessment of platelet
unction is complex. In response to activating stimuli,
latelets may release a variety of chemokines, cytokines, and
rowth factors within preformed granules; synthesize pro-
tanoids from arachidonic acid; or translate constitutively
xpressed messenger ribonucleic acid into proteins. In ad-
ition to playing a critical role in hemostasis, platelets likely
articipate in inflammatory pathways and the response to
ascular injury. Despite the complexity of platelet function,
aboratory methods for quantifying aspirin’s antithrombotic
ffect have primarily focused on the measurement of platelet
ggregation. Whether laboratory measurement of platelet
ggregation fully encapsulates aspirin’s biological effect,
owever, remains somewhat uncertain, and perhaps
oubtful.
latelet aggregation. Platelet aggregation is traditionally
easured in platelet-rich plasma using an optical aggre-
ometer. The aggregation response is stimulated by the
ddition of a platelet agonist (i.e., epinephrine, ADP, or
ollagen) and graded on a 0% to 100% scale, according to
he degree of light transmission. As platelets bind via
brinogen, light transmission increases. Although used
xtensively, this technique is labor-intensive, requires tech-
ical expertise, and the results may vary with changes in
latelet count and agonist used (32). Alternatively, whole
lood aggregometry eliminates the need to prepare platelet-
ich plasma and measures the platelet aggregation response
sing electrical impedance rather than optical density. The
esults of this technique, however, have not correlated well
ith optical aggregometry (32).
Point-of-care tests have been developed in an attempt to
ore easily measure platelet function and to monitor the
ffects of antiplatelet therapy. The platelet function analyzer
PFA)-100 system (Dade-Behring, Deerfield, Illinois) sim-
lates hemostasis by flowing whole blood through a car-
ridge that contains an aperture coated with collagen and bpinephrine or ADP (33). The time required for platelet
lug formation, aperture closure and cessation of blood flow
s used as a measure of platelet activation. The PFA-100
ystem demonstrates reasonable correlation with optical
ggregometry and has been used to measure platelet re-
ponse to aspirin therapy (10,33,34). Another point-of-care
est, the rapid platelet function assay (RPFA) (Accumetrics,
an Diego, California), is a turbidimetric-based optical
etection system that measures platelet-induced aggregation
n citrated whole blood. Concomitant glycoprotein IIb/IIIa
nhibitor, clopidogrel, dipyridamole, streptokinase, and
on-steroidal anti-inflammatory drug (NSAID) therapy
ffect the assay results. Recent studies have used the RPFA
ystem to study the association between aspirin resistance
nd cardiovascular risk (13,35).
latelet activation. Platelet activation can also be mea-
ured by the release of arachidonic acid metabolites. Urinary
evels of 11-dehydro TXB2, a stable metabolite of TXA2,
ave been used to study the extent of aspirin-mediated
nhibition of TX generation (11). However, it is not known
hether the persistent elevation in urinary TXB2 levels is
xplained simply by uninhibited platelet COX-1 activity or
erhaps also by COX-1 independent sources of TXA2
eneration. Serum markers, such as soluble CD40 ligand
nd P-selectin, have also shown promise as measurements of
latelet activation (36). To date, however, little is known
bout these markers and their correlation with platelet
ggregometry, especially in the context of aspirin therapy.
SPIRIN RESISTANCE
revalence. The concept of therapeutic resistance origi-
ated in response to the fact that the immediate biological
ffects of aspirin are not uniform among all patients. Mehta
t al. (37) demonstrated that a single 650-mg dose of aspirin
roduced minimal platelet inhibition in 30% of patients
ith coronary artery disease (CAD). Variability in aspirin-
ediated platelet inhibition has subsequently been docu-
ented among normal subjects, in patients with cerebro-
ascular disease, stable CAD, and those presenting for
oronary artery bypass surgery (7–9,38–44). Despite the
pparent consistency of these observations, the exact prev-
lence of aspirin resistance remains uncertain. The absence
f standardized diagnostic criteria or a single validated
ethod of identifying affected individuals has lead to a wide
ange of population estimates (Table 1).
linical relevance. The fact that biochemical measures of
spirin nonresponsiveness have been documented in a wide
ange of patient populations does not necessarily mean that
t has a causal association with cardiovascular disease. Even
f causal, the magnitude of risk associated with aspirin
esistance may not be clinically important. A number of
tudies have attempted to address the uncertainties between
latelet reactivity, aspirin therapy, and risk of future athero-
hrombotic events.
Clinical observations have suggested that the relationshipetween aspirin resistance and cardiovascular risk is in fact
c
w
r
p
d
a
a
2
t
b
d
(
o
b
5
s
v
A
s
M
r
w
r
t
E
o
i
t
3
c
p
i
r
m
a
c
d
a
k
i
w
d
p
t
2
c
i
e
a
i
I
L
t
S
E
I
r
v
(
r
c
2
s
a
P
n
a
a
p
w
d
u
u
p
t
s
b
t
a
t
p
e
w
a
c
t
r
N
o
y
n
o
T
G
E
G
C
C
t
990 Mason et al. JACC Vol. 46, No. 6, 2005
Aspirin Resistance and Atherothrombotic Disease September 20, 2005:986–93ausal. Grundmann et al. (41) reported that, among patients
ith prior ischemic attack or stroke, the incidence of aspirin
esistance was significantly higher (34%) as compared to a
anel of asymptomatic patients with known cerebrovascular
isease (0%). In another study, investigators reported that,
mong a population of high-risk patients taking daily
spirin therapy, the incidence of aspirin resistance was
3.4%, and individuals with a history of CAD had nearly
wice the odds of being resistant (35).
Prospective studies have further validated the relationship
etween aspirin resistance and cardiovascular risk and have
emonstrated that the magnitude of risk may not be trivial
Table 2). Grotemeyer et al. (42) reported a 30% incidence
f aspirin resistance among post-stroke patients (as defined
y a platelet reactivity index 1.25) after the ingestion of
00 mg aspirin. At two-year follow-up, the aspirin nonre-
ponders had a 10-fold increase in the risk of recurrent
ascular events as compared to aspirin-sensitive patients (7).
mong patients with intermittent claudication who pre-
ented for a peripheral vascular angioplasty procedure,
ueller et al. (45) reported a 40% incidence of aspirin
esistance. After 18 months of follow-up, aspirin resistance
as associated with an 87% increase in the risk of arterial
eocclusion. In a nested case-control study among aspirin-
reated patients within the Heart Outcome Prevention
valuation (HOPE) trial, investigators found that the risk
f MI, stroke, or cardiovascular death increased with each
ncreasing quartile of urinary 11-dehydro TXB2. Those in
he upper quartile had a 2-fold increase in risk of MI and
.5-fold increase in risk of cardiovascular death when
ompared to those in the lowest quartile (11). Among 326
atients with stable CAD presenting for cardiac catheter-
zation, Gum et al. (12) reported a 5% incidence of aspirin
esistance, as defined by optical platelet aggregation. After a
ean follow-up of 2.1 years, aspirin resistance was associ-
ted with a significant increase (hazard ratio 3.12, 95%
onfident interval 1.1 to 8.9) in the risk of MI, stroke, or
eath. More recently, Chen and colleagues (13) reported an
ssociation between aspirin resistance and creatinine
inase-MB elevation after nonurgent percutaneous coronary
ntervention procedures. In their population of 151 patients
ith stable CAD, the incidence of aspirin resistance, as
efined by the Ultegra RPFA, was 19.2%. Despite adequate
retreatment with clopidogrel and procedural anticoagula-
ion with heparin, aspirin resistance was associated with a
.9-fold increased risk of creatinine kinase-MB elevation
ompared to aspirin-sensitive patients.
able 2. Adverse Clinical Outcomes Associated With Aspirin Re
Investigators Study Population Aspirin Res
rotemeyer et al. (7) Cerebrovascular disease 30%
ikelboom et al. (11) High CVD risk Quartiles of urinar
um et al. (12) Stable CAD 5.2%
hen et al. (13) Nonurgent PCI 19.2%AD  coronary artery disease; CK  creatinine kinase; CVD  cardiovascular disease
hromboxane.Observations from large randomized clinical trials involv-
ng patients with CAD who experience atherothrombotic
vents while on aspirin therapy also support the validity of
spirin resistance and suggest that the associated risk is not
nsignificant. A post-hoc analysis of the Platelet Receptor
nhibition in Ischemic Syndrome Management in Patients
imited by Unstable Signs and Symptoms (PRISM-PLUS)
rial and a combined analysis of the Efficacy and Safety of
ubcutaneous Enoxaparin in Non–Q-wave Coronary
vents (ESSENCE) and the Thrombolysis In Myocardial
nfarction-11B (TIMI-11B) trials reported that prior aspi-
in use was an independent predictor of increased cardio-
ascular risk among patients with acute coronary syndromes
46). Similarly, investigators from the PURSUIT trial
eported that among 9,461 patients presenting with acute
oronary syndromes, those previously taking aspirin were
0% more likely to suffer a recurrent event in the following
ix months as compared to patients who were previously
spirin-naive (47).
otential mechanisms of aspirin resistance. The mecha-
ism for aspirin resistance is uncertain. The answer is likely
combination of clinical, biological, and genetic properties
ffecting platelet function (Table 3). From the clinical
erspective, behavioral habits (i.e., tobacco use), compliance
ith prescribed therapy, co-pharmacy (i.e., NSAIDs), and
uration of aspirin therapy may help contribute to individ-
al differences in aspirin responsiveness. Although tobacco
se has been shown by some investigators to increase
latelet activation and accentuate platelet thrombus forma-
ion despite aspirin-mediated suppression of TXA2 synthe-
is (48), the scientific data in support of this finding has
een inconsistent (49). Some investigators have reported
hat the increased risk of recurrent events in patients taking
spirin might be explained primarily by nonadherence to
herapy. Cotter et al. (50) reported that, among 73 patients
rescribed daily aspirin therapy after MI, the rate of adverse
vents (death, MI, or unstable angina) within 12 months
as greater among patients considered nonadherent (42%)
s compared to those considered adherent (6%) or biologi-
ally resistant (11%). The role of NSAIDs in attenuating
he long-term antithrombotic benefits of aspirin has been
eported but remains controversial (51,52). Nonselective
SAIDs have a strong binding affinity for a specific region
f platelet COX-1 and may prevent aspirin-mediated acet-
lation and enzyme inhibition. However, current data are
ot consistent or definitive in proving the clinical relevance
f this potential interaction. The duration of therapy may
nce
ce Clinical Outcomes Associated With Aspirin Resistance
10-fold increased risk of MI, death, or stroke at two years
2 levels Highest TXB2 quartile associated with a 2-fold increased
risk of MI and 3.5-fold increased risk of death when
compared to lowest quartile
3.1-fold increased risk of MI, death, or stroke at 1.8 years
2.9-fold increased risk of significant CK-MB rise after PCIsista
istan
y TXB; MI  myocardial infarction; PCI  percutaneous coronary intervention; TX 
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September 20, 2005:986–93 Aspirin Resistance and Atherothrombotic Diseaselso contribute to aspirin nonresponsiveness. Pulcinelli et al.
53) recently reported the effects of 2, 6, 12, and 24 months
f aspirin treatment (100 or 330 mg/day) on ADP and
ollagen-induced platelet aggregation among 150 subjects
ith clinical evidence of atherothrombosis. Despite ade-
uate platelet inhibitory response at two months, long-term
reatment with aspirin was associated with progressive
eduction in sensitivity to its effects. The investigators also
eported, consistent with previous observations, that the
ensitivity to aspirin was not dose-dependent.
The redundancy of platelet activation pathways and
eceptors may contribute to the problem of aspirin resis-
ance. More specifically, pathways involving non–TXA2-
ependent activators such as, thrombin, ADP, epinephrine,
nd collagen can bypass the aspirin-mediated inhibitory
ffect leading to platelet activation and thrombosis.
atecholamine-induced platelet aggregation is one such
athway that might not be adequately inhibited by aspirin.
urlen et al. (54) reported that, among patients with a
revious MI, aspirin achieved adequate antiplatelet effects at
est but failed to inhibit exercise-induced increases in
latelet aggregation. Similarly, aspirin pretreatment among
ealthy volunteers has been shown to attenuate basal plate-
et aggregability but not the effect of norepinephrine infu-
ion on platelet aggregation (55). Both observations suggest
hat the antiplatelet effects of aspirin may be overcome
uring periods of increased sympathetic nervous system
ctivity, such as during exercise or mental stress. Finally,
here is evidence to suggest that aspirin nonresponders may
ave increased platelet sensitivity to collagen (56).
Alternate pathways for TXA2 synthesis and the identifi-
ation of prostaglandin-like compounds (isoprostanes) also
rovide potential explanations for the syndrome of aspirin
esistance. Aspirin-insensitive TXA2 biosynthesis can occur
s a result of COX-2 induction in nonplatelet cells (mono-
ytes/macrophages or endothelial cells) resulting from local
able 3. Potential Mechanisms of Aspirin Resistance
Clinical
1) Noncompliance with prescribed aspirin therapy
2) Tobacco: enhanced platelet function
Pharmacodynamic
1) Dose-response: the antiplatelet or anti-inflammatory effects of aspiri
2) Duration of therapy: the biological response to aspirin might be red
3) Drug interactions: NSAIDs might inhibit aspirin-mediated COX-1
Biological
1) Aspirin-insensitive TXA2 biosynthesis: inducible COX-2, or regener
augment TXA2 production
2) Alternate pathways for platelet activation:
a) Increased collagen sensitivity in aspirin nonresponders may lead to
b) Failure to inhibit catecholamine-mediated (e.g., exercise, mental s
c) Failure to inhibit non-TXA2-mediated (e.g., adenosine diphospha
3) Prostaglandin-like compounds: isoprostanes are produced from arach
4) Vascular inflammation: increased platelet membrane expression of C
to platelet-mediated participation in vascular inflammation
Genetic
1) Mutations and/or polymorphisms of the COX-1 gene: may prevent
2) Glycoprotein IIb/IIIa receptor polymorphisms (PIA2)
OX  cyclooxygenase; NSAID  non-steroidal anti-inflammatory drug; TX  thnflammatory stimuli (20,57). These cells can both release PXA2 or provide its precursor, PGH2, to the aspirin-
nhibited platelets. Additionally, COX-2 is present in newly
ormed platelets and may account for detectable levels of
XA2 synthesis during periods of increased platelet turn-
ver (19). Isoprostanes, resulting from lipid peroxidation,
irculate at increased concentrations in patients with unsta-
le angina, diabetes mellitus, hyperlipidemia, and in ciga-
ette smokers. In addition, acting as vasoconstrictors, iso-
rostanes may have a role in amplifying the response of
latelets to other agonists (18,58).
The interaction of platelets with other cells, such as eryth-
ocytes or vascular endothelial cells, may also affect aspirin-
ediated inhibition. It has been demonstrated, for example,
hat erythrocytes induce an increase in platelet TXB2 synthesis
nd release of serotonin, beta-thromboglobulin, and ADP.
revious investigation among patients with known vascular
isease demonstrated that aspirin (200 to 300 mg daily)
ncompletely blocks platelet reactivity in up to two-thirds of
atients in the presence of erythrocytes despite adequate
nhibition of platelet TXA2 synthesis (59). As stated previ-
usly, the effect of aspirin-mediated inhibition of endothelium-
erived PGI2 production is not entirely known but may play a
ole in antagonizing the antithrombotic effects of aspirin at
igher doses (17). The increased concentration of circulating
latelet-monocyte aggregates during acute atherothrombotic
vents represents an accepted link between inflammation and
hrombosis. There is growing evidence that CD40-CD40
igand interactions might play an important role in both
latelet activation, arterial thrombosis, and platelet-mediated
athways of vascular inflammation (36). To what extent
latelet CD40 ligand expression and CD40-CD40 ligand
nteractions are inhibited by aspirin is in large part unknown.
Lastly, aspirin resistance might in part be explained by
enetic differences in the COX-1 gene or the glycopro-
ein IIb/IIIa receptor complex. Polymorphisms of the
IIa subunit have been identified, and specific alleles,
ht be dose-related
ith long-term therapy
lation and attenuate the long-term antithrombotic benefits of aspirin
COX-1, activity in macrophages and vascular endothelial cells may
ased platelet adhesion
epinephrine) platelet activation
atet-activating factor, and thrombin) platelet activation
c acid and lipid peroxidation and may have properties similar to TXA2
ligand may represent a novel pathway of platelet activation and/or a link
n-mediated COX-1 acetylation
xane.n mig
uced w
acety
ated
incre
tress,
te, pl
idoni
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aspirilAI/A2 and PlA2/A2, are associated with increased throm-
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ion, alpha-granule release, and fibrinogen binding (Ta-
le 3). The antithrombotic effects of aspirin might be
ttenuated among carriers of the PlA2 polymorphism
60,61). Although unproven, it has been suggested that
utations and/or polymorphisms of the COX-1 gene
ay also help to explain the structural basis for aspirin
esistance in some patients (20).
UTURE DIRECTIONS
everal studies have reported variable platelet response and
otential therapeutic resistance to thienopyridines (62–65),
nd clopidogrel resistance has recently been linked to
dverse clinical outcomes (65,66). However, similar to the
tudy of aspirin resistance, there is no standardized defini-
ion of clopidogrel resistance, and further investigation is
ecessary to determine its population prevalence, clinical
ignificance, and biological mechanism. Although less well-
stablished, resistance to other antithrombotic therapies,
uch as glycoprotein IIb/IIIa antagonists, is biologically
lausible and may in part explain some of the variability in
atient response to these therapies.
ONCLUSIONS
spirin resistance remains broadly defined but appears to
epresent a valid and important biological phenomenon
ith significant clinical implications. There is substantial
vidence to suggest that a significant percentage of
ndividuals who take aspirin demonstrate resistance to its
ntithrombotic effects, as measured by one or more
aboratory tests. Additionally, there is growing evidence
hat laboratory measures of aspirin nonresponsiveness
ay predict increased risk of future atherothrombotic
vents.
There are, however, many unanswered questions that
eed to be addressed before applying the concept of
spirin resistance to clinical practice and risk stratifica-
ion. Principal among the uncertainties are: 1) the lack of
standardized definition and validated method of iden-
ifying aspirin resistance; 2) the unknown prevalence of
spirin resistance within the population; 3) the absence of
clearly defined biological mechanism for aspirin resis-
ance; 4) the uncertain clinical relevance of aspirin
esistance in cardiovascular risk prevention; and 5) the
bsence of a proven therapeutic strategy for affected
ndividuals. Some of these questions may be addressed in
he Clopidogrel for High Atherothrombotic Risk and
schemic Stabilization Management and Avoidance
CHARISMA) trial, an ongoing randomized clinical trial
valuating the combination of aspirin plus clopidogrel
ersus aspirin alone in both secondary prevention and
igh-risk primary prevention. Until then, aspirin remains
proven, and powerful, therapy against the atherothrom-
otic complications of cardiovascular disease. 1eprint requests and correspondence: Dr. Peter J. Mason,
righam and Women’s Hospital, Division of Cardiovascular
edicine, 75 Francis Street, Boston, Massachusetts 02115.
-mail: pjmason@partners.org.
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